Prebiotic inulin-type fructans and galacto-oligosaccharides: definition, specificity, function, and application in gastrointestinal disorders

Journal of Gastroenterology and Hepatology (Australia)

Volumn 32, Issue , 2017, Pages 64-68

  Wilson, Bridgette ^a   Whelan, Kevin ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

galacto oligosaccharides; inulin; irritable bowel syndrome; low FODMAP; prebiotics

Indexed keywords

FRUCTAN; GALACTOSE OLIGOSACCHARIDE; INULIN; INULIN TYPE FRUCTAN PREBIOTIC AGENT; PREBIOTIC AGENT; UNCLASSIFIED DRUG; DISACCHARIDE; GALACTOSE; MONOSACCHARIDE; OLIGOSACCHARIDE; POLYMER; POLYOL;

CROHN DISEASE; DIET THERAPY; DIETARY INTAKE; DRUG EFFICACY; GASTROINTESTINAL DISEASE; HUMAN; IMMUNOMODULATION; INTESTINE FLORA; IRRITABLE COLON; LOW CARBOHYDRATE DIET; LOW FODMAP DIET; NONHUMAN; PRIORITY JOURNAL; REVIEW; SPECIES DIFFERENCE; BIFIDOBACTERIUM; DIETARY SUPPLEMENT; GROWTH, DEVELOPMENT AND AGING; IMMUNOLOGY; MICROBIOLOGY;

BIFIDOBACTERIUM; CROHN DISEASE; DIET, CARBOHYDRATE-RESTRICTED; DIETARY SUPPLEMENTS; DISACCHARIDES; FRUCTANS; GALACTOSE; GASTROINTESTINAL MICROBIOME; HUMANS; IRRITABLE BOWEL SYNDROME; MONOSACCHARIDES; OLIGOSACCHARIDES; POLYMERS; PREBIOTICS;

EID: 85014021507     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/jgh.13700     Document Type: Review

References (30)

1. Roberfroid M, Gibson GR, Hoyles L et al. Prebiotic effects: metabolic and health benefits. Br. J. Nutr. 2010; 104: S1–S63.
2. Tzortzis G, Vulevic J. Galacto-oligosaccharide prebiotics. In: Prebiotics and Probiotics Science and Technology. New York, USA: Springer, 2009; 207–244.
3. Xiaoli X, Liyi Y, Shuang H et al. Determination of oligosaccharide contents in 19 cultivars of chickpea (Cicer arietinum L) seeds by high performance liquid chromatography. Food Chem. 2008; 111: 215–219.
4. Brummer Y, Kaviani M, Tosh SM. Structural and functional characteristics of dietary fibre in beans, lentils, peas and chickpeas. Food Res. Int. 2015; 67: 117–125.
5. Vulevic J, Rastall RA, Gibson GR. Developing a quantitative approach for determining the in vitro prebiotic potential of dietary oligosaccharides. FEMS Microbiol. Lett. 2004; 236: 153–159.
6. Sonnenburg ED, Zheng H, Joglekar P et al. Specificity of polysaccharide use in intestinal bacteroides species determines diet-induced microbiota alterations. Cell 2010; 141: 1241–1252.
7. Kolida S, Meyer D, Gibson GR. A double-blind placebo-controlled study to establish the bifidogenic dose of inulin in healthy humans. Eur. J. Clin. Nutr. 2007; 61: 1189–1195.
8. Hinz SW, Van den Broek LA, Beldman G, Vincken J-P, Voragen AG. β-Galactosidase from Bifidobacterium adolescentis DSM20083 prefers β (1, 4)-galactosides over lactose. Appl. Microbiol. Biotechnol. 2004; 66: 276–284.
9. Depeint F, Tzortzis G, Vulevic J, I'Anson K, Gibson GR. Prebiotic evaluation of a novel galactooligosaccharide mixture produced by the enzymatic activity of Bifidobacterium bifidum NCIMB 41171, in healthy humans: a randomized, double-blind, crossover, placebo-controlled intervention study. Am. J. Clin. Nutr. 2008; 87: 785–791.
10. Vulevic J, Juric A, Walton GE et al. Influence of galacto-oligosaccharide mixture (B-GOS) on gut microbiota, immune parameters and metabonomics in elderly persons. Br. J. Nutr. 2015; 114: 586–595.
11. Delgado GTC, Thomé R, Gabriel DL, Tamashiro WM, Pastore GM. Yacon (Smallanthus sonchifolius)-derived fructooligosaccharides improves the immune parameters in the mouse. Nutr. Res. 2012; 32: 884–892.
12. Vogt L, Meyer D, Pullens G et al. Immunological properties of inulin-type fructans. Crit. Rev. Food Sci. Nutr. 2015; 55: 414–436.
13. De Filippo C, Cavalieri D, Di Paola M et al. Impact of diet in shaping gut microbiota revealed by a comparative study in children from Europe and rural Africa. Proc. Natl. Acad. Sci. 2010; 107: 14691–14696.
14. O'Keefe SJ, Li JV, Lahti L. Fat, fibre and cancer risk in African Americans and rural Africans. Nature Commun. 2015; 6: 6342.
15. Bennet SM, Ohman L, Simren M. Gut microbiota as potential orchestrators of irritable bowel syndrome. Gut Lliver. 2015; 9: 318–331.
16. Rajilic-Stojanovic M, Biagi E, Heilig HG et al. Global and deep molecular analysis of microbiota signatures in fecal samples from patients with irritable bowel syndrome. Gastroenterology 2011; 141: 1792–1801.
17. Jalanka-Tuovinen J, Salonen A, Nikkila J et al. Intestinal microbiota in healthy adults: temporal analysis reveals individual and common core and relation to intestinal symptoms. PLoS One 2011; 6: e23035.
18. Whelan K. Mechanisms and effectiveness of prebiotics in modifying the gastrointestinal microbiota for the management of digestive disorders. Proc. Nutr. Soc. 2013; 72: 288–298.
19. Silk DBA, Davis A, Vulevic J, Tzortzis G, Gibson GR. Clinical trial: The effects of a trans-galactooligosaccharide prebiotic on faecal microbiota and symptoms in irritable bowel syndrome. Aliment. Pharmacol. Ther. 2009; 29: 508–518.
20. Lindsay JO, Whelan K, Stagg AJ et al. Clinical, microbiological, and immunological effects of fructo-oligosaccharide in patients with Crohn's disease. Gut 2006; 55: 348–355.
21. Benjamin JL, Hedin CR, Koutsoumpas A et al. Randomised, double-blind, placebo-controlled trial of fructo-oligosaccharides in active Crohn's disease. Gut 2011; 60: 923–929.
22. Joossens M, De Preter V, Ballet V, Verbeke K, Rutgeerts P, Vermeire S. Effect of oligofructose-enriched inulin (OF-IN) on bacterial composition and disease activity of patients with Crohn's disease: results from a double-blinded randomised controlled trial. Gut 2012; 61: 958.
23. Hedin CR, Mullard M, Sharratt E et al. Probiotic and prebiotic use in patients with inflammatory bowel disease: a case–control study. Inflamm. Bowel Dis. 2010; 16: 2099–2108.
24. Anderson JL, Hedin CR, Benjamin JL et al. Dietary intake of inulin-type fructans in active and inactive Crohn's disease and healthy controls: a case–control study. J. Crohns Colitis 2015; 9: 1024–1031.
25. Staudacher HM, Irving PM, Lomer MC, Whelan K. Mechanisms and efficacy of dietary FODMAP restriction in IBS. Nat. Rev. Gastroenterol. Hepatol. 2014; 11: 256–266.
26. Prince AC, Myers CE, Joyce T, Irving P, Lomer M, Whelan K. Fermentable carbohydrate restriction (low FODMAP diet) in clinical practice improves functional gastrointestinal symptoms in patients with inflammatory bowel disease. Inflamm. Bowel Dis. 2016; 22: 1129–1136.
27. Gearry RB, Irving PM, Barrett JS, Nathan DM, Shepherd SJ, Gibson PR. Reduction of dietary poorly absorbed short-chain carbohydrates (FODMAPs) improves abdominal symptoms in patients with inflammatory bowel disease—a pilot study. J. Crohns Colitis 2009; 3: 8–14.
28. Staudacher HM, Lomer MC, Anderson JL et al. Fermentable carbohydrate restriction reduces luminal bifidobacteria and gastrointestinal symptoms in patients with irritable bowel syndrome. J. Nutr. 2012; 142: 1510–1518.
29. Halmos EP, Power VA, Shepherd SJ, Gibson PR, Muir JG. A diet low in FODMAPs reduces symptoms of irritable bowel syndrome. Gastroenterology 2014; 146: 67–75.e5
30. Halmos EP, Christophersen CT, Bird AR, Shepherd SJ, Muir JG, Gibson PR. Consistent prebiotic effect on gut microbiota with altered FODMAP intake in patients with Crohn's disease: a randomised, controlled cross-over trial of well-defined diets. Clin. Transl. Gastroenterol. 2016; 7: e164.